Need, feasibility and convenience of dosimetric treatment planning in liver selective internal radiation therapy with 90Y microspheres: The experience of the National Cancer Institute of Milan

Quarterly Journal of Nuclear Medicine and Molecular Imaging

Volumn 55, Issue 2, 2011, Pages 168-197

  Chiesa, C ^a   Maccauro, M ^a   Romito, R ^a   Spreafico, C ^a   Pellizzari, S ^b   Negri, A ^c   Sposito, C ^a   Morosi, C ^a   Civelli, E ^a   Lanocita, R ^a   Camerini, T ^a   Bampo, C ^c   Bhoori, S ^a   Seregni, E ^a   Marchiano A ^a   Mazzaferro, V ^a   Bombardieri, E ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

Author keywords

Clinical protocols; Dosimetry, treatment planning; Liver; Microspheres

Indexed keywords

ALKALINE PHOSPHATASE; AMINOTRANSFERASE; BILIRUBIN; GLASS; MICROSPHERE; RESIN; YTTRIUM 90;

ARTIFICIAL EMBOLISM; ASCITES; BODY SURFACE; CANCER RADIOTHERAPY; COLORECTAL CANCER; COMPARATIVE EFFECTIVENESS; COMPUTER ASSISTED TOMOGRAPHY; DISEASE EXACERBATION; DOSIMETRY; EXTERNAL BEAM RADIOTHERAPY; FATALITY; HUMAN; INTERMETHOD COMPARISON; ITALY; JAUNDICE; LIVER DOSIMETRY; LIVER EXAMINATION; LIVER FAILURE; LIVER METASTASIS; LIVER TOXICITY; NATIONAL HEALTH ORGANIZATION; RADIATION DOSE DISTRIBUTION; RADIATION DOSE FRACTIONATION; RADIATION PNEUMONIA; RADIOACTIVITY; RADIOEMBOLIZATION; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TREATMENT FAILURE; TREATMENT PLANNING; TUMOR DOSIMETRY; TUMOR VOLUME; VOXEL DOSIMETRY; WORK EXPERIENCE;

ACADEMIES AND INSTITUTES; CARCINOMA, HEPATOCELLULAR; DOSE-RESPONSE RELATIONSHIP, RADIATION; EMBOLIZATION, THERAPEUTIC; HUMANS; ITALY; LIVER; LIVER NEOPLASMS; MICROSPHERES; MODELS, BIOLOGICAL; RADIATION PNEUMONITIS; RADIOBIOLOGY; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED; YTTRIUM RADIOISOTOPES;

EID: 79957645804     PISSN: 18244785     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (69)

1. World Health Organization, Cancer Fact Sheet www.who.int/mediacentre/ factsheets/fs297/en/index.html
2. Michel J, Suc B, Montpeyroux F, Hachemanne S, Blanc P, Domergue J et al. Liver resection or transplantation for hepatocellular carcinoma ? Retrospective analysis of 215 patients with cirrhosis. J Hepatol 1997;26:1274-80. (Pubitemid 27346640)
3. Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patient with cirrhosis. N Eng J Med 1966;34:693-9.
4. Monsieurs MA, Bacher K, Brans B, Vral A, De Ridder L, Dierckx RA et al. Patient dosimetry for 131I-lipiodol therapy Eur J Nucl Med Mol Im 2003;30:554-61.
5. Bacher K, Brans B, Monsieurs M, De Winter F, Dierckx RA, Thierens H Thyroid uptake and radiation dose after (131)I-lipiodol treatment: is thyroid blocking by potassium iodide necessary? Eur J Nucl Med Mol Imaging 2002;29:1311-6.
6. Table of nucleids. Available from http://atom.kaeri.re.kr/ [cited 2011, Feb 1].
7. Strigari L, Sciuto R, Rea S, Carpanese L, Pizzi G, Soriani A et al. Efficacy and toxicity related to treatment of hepatocellular carcinoma with 90Y SIR spheres: radiobiologic considerations. J Nucl Med 2010;51:1377-85.
8. Lhommel R, Goffette P, Van den Eynde M, Jamar F, Pauwels S, Bilbao JI et al. Yttrium-90 TOF PET scan demonstrates high-resolution biodistribution after liver SIRT. Eur J Nucl Med Mol Imaging 2009;36:1696.
9. Sirtex. SIR-Spheres. Available from http://www.sirtex.com/files/TRN-US- 0320for20US1.pdf [cited 2011, Feb 1].
10. Sirtex. SIR-Spheres® microspheres. Available from http://www.sirtex.com/files/US20Package20Insert1.pdf [cited 2011, Feb 1].
11. TheraSphere® Yttrium-90 Glass Microspheres Instructions for Use. Available from http://www.mdsnordion.com/therasphere/physicians-package-insert/ package-insert-eu-en.pdf [cited 2011, Feb 1].
12. Knesaurek K, Machac J, Muzinic M, DaCosta M, Zhuangyu Z, Heiba S. Quanitative comparison of yttrium-90 (90Y)-microspheres and technecium-99m (99mTc)-macroaggregated albumin SPECT images for planning 90Y therapy of liver cancer. Technol Cancer Res Treat 2010;9:253-61.
13. Flamen P, Vanderlinde B, Delatte P, Ghanem G, Ameye L, Van Den Eynde M et al. Multimodality imaging can predict the metabolic response of unresectable colorectel liver metastases to radioembolization therapy with yttrium-90 labeled resin micropheres. Phys Med Biol 2008;53:6591-603.
14. Ho S, Lau WY, Leung TWT, Chan M, Ngar YK, Johnson PJ. Partition model for estimating radiation doses from yttrium-90 micropheres in treating hepatic tumours. Eur J Nucl Med 1996;23:947-52 (Pubitemid 26278795)
15. Sarfaraz M, Kennedy AS, Cao ZJ, Sackett GD, Yu CX, Lodge MA et al. Physical aspects of yttrium-90 microsphere therapy for non respectable hepatic tumours. Med Phys 2003;30:199-203 (Pubitemid 36222855)
16. Kennedy AS, McNeillie P, Dezarn WA, Nutting C, Sangro B, Wertman D et al. Treatment parameters and outcome in 680 treatments of internal radiation with resin 90Y-microspheres for unresectable hepatic tumours. Int J Onc Biol Phys 2009;74:1494-500.
17. Salem R, Thurstone J. Radioembolization with yttrium-90 Microspheres: a state-of-the-art brachytherapy treatment for primary and secondary liver malignancies Part 1: technical and methodologic considerations. Vasc Interv Radiology 2006:17;1251-78 (Pubitemid 44259009)
18. Chiesa C, Azzeroni R, Maccauro M, Mansi D, Spreafico C, Morosi C et al. High doses delivered to hepatocellular carcinoma with 90Y glass microspheres. A dosimetric study. Eur J Nucl Med Mol Im 2008;35(Suppl 2):P269.
19. Gulec SA, Mesoloras G, Stabin M. Dosimetric techniques in Y-90 microsphere therapy of liver cancer: the MIRD equation for dose calculations. J Nucl Med 2006;47:1209-11. (Pubitemid 47544917)
20. 90Y TOF PET-based dosimetry in liver metastasis therapy using SIR-Spheres Eur J Nucl Med Mol Imaging 2010;37:1654-62.
21. Emami B, Lyman J, Brown A, Coia L, Goitein M, Munzenrider JE et al. Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys 1991;21:109-22.
22. Burman C, Kutcher GJ, Emami B, Goitein M. Fitting of normal tissue tolerance data to an analytic function. Int J Radiat Oncol Biol Phys 1991;21:123-35.
23. Dawson LA, Ten Haken RK. Partial volume tolerance of the liver to radiation. Sem Rad Oncol 2005;15:279-83. (Pubitemid 41377144)
24. 90Y-DOTATOC: relevance of kidney volume and dose rate in finding a dose-effect relationship. J Nucl Med 2005;46:99S-106S.
25. Wessels BW, Konijnenberg MW, Dale RG, Breitz HB, Cremonesi M, Meredith RF et al. MIRD Pamphlet No. 20: the effect of model assumptions on kidney dosimetry and response - implications for radionuclide therapy. J Nucl Med 2008;49:1884-9.
26. Lyman JT. Complication probability as assessed from dose volume hystograms. Radiat Res 1985;104:S13-S19 (Pubitemid 16149302)
27. Cheng JCH, Wu JK, Lee PCT, Liu HS, Jian JJM, Lin YM et al. Biologic susceptibility of hepatocellular carcinoma patients treated with radiotherapy to radiation induced liver disease. Int J Radiat Onc Biol Phys 2004;60:1502-9.
28. Jackson A, Ten Haken RK, Robertson JM, Kessler ML, Kutcher GJ, Lawrence TS. Analysis of clinical complication data for radiation hepatitis using a parallel architecture model. Int J Radiat Oncol Biol Phys 1995;31:883-91.
29. Dawson LA, Lawrence TS, Yen Haken RK. Partial liver irradiation. Semin Radiat Onc 2001;11:240-6.
30. Riaz A, Lewandowski RJ, Kulik L, Mulcahy MF, Sato KT, Ryu RK et al. Complications following radioembolization with yttrium-90 microspheres: a comprehensive literature review. J Vasc Interv Radiol 2009;20:1121-30.
31. Dancey JE, Sheperd FA, Paul K, Sniderman KW, Houle S, Gabrys J et al. Treatment of non resectable hepatocellular carcinoma with intrahepatic 90Y-microspheres. J Nucl Med 2000;41:1673-81.
32. Ho S, Lau JWY, Leung TWT. Intrahepatic 90-Y microspheres for hepatocellular carcinoma letter to the editor. J Nucl Med 2001;42:1587-9. (Pubitemid 32953142)
33. Goin JE, Salem R, Carr BI, Dancey JE, Soulen MC, Geschwind JFH et al. Treatment of unresectable hepatocellular carcinoma with intrahepatic yttrium 90 microspheres: a risk-stratification analysis J Vasc Interv Radiol 2005;16:195-203. (Pubitemid 40322292)
34. Goin JE, Salem R, Carr BI, Dancey JE, Soulen MC, Geschwind JFH et al. Treatment of unresectable hepatocellular carcinoma with intrahepatic yttrium 90 microspheres: factors associated with liver toxicities. J Vasc Interv Radiol 2005;16:205-13. (Pubitemid 40322293)
35. Rhee TK, Omary RA, Gates V, Mounajjed T, Larson AC, Barakat et al. The effect of catheter-direct CT angiography on yttrium-90 radioembolization treatment of hepatocellular carcinoma. J Vasc Interv Radiol 2005;16:1085-91. (Pubitemid 41177121)
36. Riaz A, Gates VL, Atassi B, Lewandowski RJ, Mulcahy MF, Ryu RK et al. Radiation segmentectomy: a novel approach to increase safety and efficacy of radioembolization. Under publication on Int J Radiat Onc Biol Phys 2011;79:163-71.
37. WHO Handbook for reporting results for cancer treatment. Available from http://whqlibdoc.who.int/publications/9241700483.pdf [cited 2011, Feb 1].
38. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L et al. New Guidelines to Evaluate the Response to Treatment in Solid Tumours. J Natl Cancer Inst 2000;92:205-16. (Pubitemid 30099779)
39. Young JY, Rhee TK, Atassi B, Gates VL, Kulik L, Mulcahni MF et al. Radiation dose limits and liver toxicities resultin from multiple yttrium-90 radioembolization treatments for hepatocellular carcinoma. J Vasc Interv Radiol 2007;18:1375-82.
40. Grieco A, Pompili M, Caminiti G, Miele L, Covino M, Alfei B et al. Prognostic factors for survival in patients with early-intermediate hepatocellular carcinoma undergoing non-surgical therapy: comparison of Okuda, CLIP, and BCLC staging systems in a single Italian centre. Gut 2005;54:411-8. (Pubitemid 40299100)
41. Hilgard P, Hamami M, El Fouly A, Scherag A, Müller S, Ertle et al. Radioembolization with yttrium-90 glass microspheres in hepatocellular carcinoma: European Experience on Safety and Long-Term Survival. Hepatology 2010;52:1751-9.
42. Sangro B, Gil-Alzugaray B, Rodriguez J, Sola I, Martinez-Questa A, Viudez A et al. Liver disease induced by radioembolization of liver tumours. Cancer 2008;112:1539-46.
43. Cremonesi M, Ferrari M, Bartolomei M, Orsi F, Bonomo G, Aricò D et al. Radioembolization with 90Y-microspheres: dosimetric and radiobiological investigation for multi-cycle treatment. Eur J Nucl Med Mol Imaging 2008;35:2088-96.
44. Leung TW, Lau WY, Ho SK. Radiation pneumonitis after selective internal radiation treatment with intraarterial 90yttrium microspheresfor inoperable hepatic tumours. Int J Radiat Onc Biol Phys 1995;33:919-24.
45. Ho S, Lau WY, Leung TWT, Chan M, Johnson PJ, Li AKC. Clinical evaluation of the partition model for estimatine radiation doses from yttrium-90 mirospheres in the treatment of hepatic cancer. Eur J Nucl Med 1997;24:293-8. (Pubitemid 27165858)
46. Salem R, Parikh P, Atassi B, Lewandowski RJ, Ryu RK, Sato KT et al. Incidence of radiation pneumonitis after hepatic intraarterial radiotherapy with yttrium-90 microspheres asssuming uniform lung distribution. Am J CLin Onc 2008;31:431-8.
47. Campbell JM, Wong CO, Muzik O, Marples B, Joiner M, Burmeister J. Early dose response to yttrium-90 microsphere treatment of metastatic liver cancer by a patient-specific method using single photon emission computed tomography and positron emission tomography. Int J Radiat Oncol Biol Phys 2009;74:313-20.
48. Steel GG. The dose rate effect: Brachytherapy and targeted radiotherapy. In Steel GG editor. Basic clinical radiobiology. 3rd edition. London: UK Arnold; 2002. p. 192-204.
49. Garin E, Rolland Y, Pracht M, Lenoir L, Ardisson V, Laffont S et al. 99mTc-MAA SPECT/CT accurately predict tumoural response for patients treated with 90Y-microsphere for hepatocellular carcinoma. Eur J Nucl Med Mol Im 2010;37(Suppl 2):S292 OP535.
50. Lhommel R, van Elmbt L, Goffette P, Van den Eynde M, Jamar F, Pauwels S et al. Feasibility of 90Y TOF PET-based dosimetry in liver metastasis therapy using SIR-Spheres Eur J Nucl Med Mol Imaging 2010;37:1654-62.
51. Sarfaraz M, Kennedy AS, Lodge MA, Li AX, Wu X, Yu CX. Radiation absorbed dose distribution in a patient treated with yttrium-90 microspheres for hepatocellular carcinoma. Med Phys 2004;31:2449-53. (Pubitemid 39287858)
52. Di Dia A, Botta F, Cremonesi M, Ferrari M, Bartolomei M, Orsi F et al. Dosimetric evaluation in 90Y micropheres treatment of liver metastasis: comparison of planar standard 3D dosimetry and voxel dosimetry methods. Eur J Nucl Med Mol Im 2010:37(Suppl 2):S292 OP536
53. Chiesa C, Pellizzari S, Negri A, Maccauro M, Morosi C, Romito R et al. Voxel dosimetry in SIRT of primary hepato-cellular carcinoma with 90-Y glass microsphere: correlation between equivalent uniform dose and tumour response allows treatment planning based on real dosimetry. Eur J Nucl Med Mol Im 2010;37(Suppl 2):S291 OP533.
54. Pacilio M, Lanconelli N, Lo Meo S, Torres L, Coca Perez M; Botta F et al. www.df.unibo.it/medphys
55. Jones LC, Hoban PW. Treatment plan comparison using equivalent uniform biologically effective dose (EUBED). Phys Med Biol 2000;45:159-70. (Pubitemid 30060666)
56. O'Donoghue J. Implications of nonuniform tumour doses for radioimmunotherapy. J Nucl Med 1999;40:1337-41. (Pubitemid 29385643)
57. Fox RA, Phil D, Klemp PFB, Egan G, Mina LL, Burton MA et al. Dose distribution following selective internal radiation therapy. Int J Radiation Oncology Biol Phys 1991;21:463-7.
58. Russels JL, Carden JL, Herron HL. Dosimetry calculation for yttrium-90 used in the treatment of liver cancer. Endocuriether. Hyperther Oncol 1988;4:171-86.
59. Yorke ED, Jackson A, Fox RA, Wessels BW, Gray BN. Can current models explain the lack of liver complications in Y-90 microsphere therapy? Clin Cancer Res 1999;5 Suppl:3024s-3030s.
60. Andrews JC, Walzer SC, Ackermann RJ, Cotton LA, Esminger WD, Shapiro B. Hepatic radioembolization with yttrium-90 containing glass microspheres: preliminary results and clinical follow up. J Nucl Med 1994;35:1637-44.
61. 90Y microspheres in man: review of four explanted whole livers. Int J Radiat Oncol Biol Phys 2004;60:1552-63. (Pubitemid 39601873)
62. Pillai KM, McKeever PE, Knutsen CA, Terrio PA, Prieskorn DM, Ensminger WD. Microscopic analysis of arterial microsphere distribution in rabbit liver and hepatic VX2 tumour. Sel Cancer Ther1991;7:39-48.
63. Campbell AL, Bailey IH, Burton MA. MA Tumour dosimetry in human liver following hepatic yttrium-90 microsphere therapy. Phys Med Biol 2001;46:487-98. (Pubitemid 32148511)
64. Campbell AM, Bailey IH, Burton MA. Analysis of the distribution of intra-arterial microspheres in human liver following hepatic yttrium-90 microsphere therapy. Phys Med Biol 2000;45;1023-33. (Pubitemid 30196393)
65. Gulec SA, Szteinnberg ML, Siegel JA, Jevremovic T, Stabin M. Hepatic structural dosimetry in 90-Y microsphere treatment: a Monte Carlo modeling approach based on lobular microanatomy. J Nucl Med 2010;51:301-10.
66. Gaba RC, Lewandowsi RJ, Kulik LM, Riaz A, Ibrahim SM, Mulcahy MF. Radiation lobectomy: preliminary findings of hepatic volumetric response to lobar yttrium-90 radioembolization Ann Surg Oncol 2009;16:1587-96.
67. 90Y-ibritumomab tiuxetan (ZEVALIN®). Eur J Nucl Med Mol Imaging 2009;36:1745-57.
68. Councile directive 97/43 EURATOM. Available from: http://ec.europa.eu/ energy/nuclear/radioprotection/doc/legislation/9743-en.pdf [cited 2011, Feb 1].
69. Dieudonné A, Hobbs RF, Bolch WE, Sgouros G, Sgouros G, Gardin I. Fine-resolution voxel s values for constructing absorbed dose distributions at variable voxel size. J Nucl Med 2010;51:1600-7.